Brookline Cap M Estimates IceCure Medical Q1 Earnings

IceCure Medical Ltd. (NASDAQ:ICCM) – Research analysts at Brookline Cap M issued their Q1 2026 EPS estimates for IceCure Medical in a report issued on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver anticipates that the company will earn ($0.03) per share for the quarter. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Cap M also issued estimates for IceCure Medical’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2030 earnings at $0.22 EPS.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $1.28 million for the quarter, compared to the consensus estimate of $1.30 million. IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 221.04%.

Several other research analysts also recently issued reports on ICCM. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, IceCure Medical has a consensus rating of “Hold” and an average price target of $2.64.

IceCure Medical Price Performance

Shares of NASDAQ:ICCM opened at $0.63 on Thursday. IceCure Medical has a one year low of $0.54 and a one year high of $1.40. The company has a market cap of $45.95 million, a price-to-earnings ratio of -2.62 and a beta of 0.29. The firm has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.74.

Institutional Investors Weigh In On IceCure Medical

A number of institutional investors have recently added to or reduced their stakes in ICCM. Virtu Financial LLC acquired a new position in IceCure Medical in the 4th quarter valued at approximately $39,000. Concurrent Investment Advisors LLC bought a new position in shares of IceCure Medical during the fourth quarter valued at $48,000. Finally, Jane Street Group LLC acquired a new position in shares of IceCure Medical during the fourth quarter worth $67,000. 0.62% of the stock is owned by institutional investors.

IceCure Medical News Roundup

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: New peer‑reviewed PLOS One data highlighted by the company show its ProSense cryoablation is effective for treating breast fibroadenomas — a clinical win that supports product utility and potential commercial adoption if follow‑on studies/commercialization progress. IceCure Medical Highlights New PLOS One Data Showing ProSense Cryoablation Effective for Breast Fibroadenomas
• Positive Sentiment: Brookline Cap M’s long‑range model includes positive multi‑year estimates (FY2029/FY2030 projections) that suggest some analysts see upside over the longer term despite near‑term weakness — this can act as a tailwind if execution and commercial uptake match assumptions. ICCM on MarketBeat
• Neutral Sentiment: Q4 2025 earnings call transcript is available for review — useful for investors wanting management commentary on sales, clinical programs and cash burn after the recent quarterly miss. That context may influence positioning but is informational rather than a new catalyst. IceCure Medical Ltd (NASDAQ:ICCM) Q4 2025 earnings call transcript
• Negative Sentiment: Brookline Cap M issued a series of downward revisions to near‑term EPS estimates (cuts to FY2026, FY2027 and FY2028 and lowered quarterly 2026 EPS projections). Those model cuts lower near‑term profitability expectations and are the primary negative driver weighing on the stock today. ICCM on MarketBeat
• Negative Sentiment: Recent fundamental metrics (recent quarterly EPS miss, negative margins and high negative ROE) combined with the analyst downgrades increase downside risk until management can show consistent revenue growth or margin improvement. Investors should expect continued volatility around execution updates and clinical/commercial milestones. ICCM on MarketBeat

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.